Drug development – Page 27

Lead candidate fails downstream criteria before IND-enabling studies – how to avoid late-stage attrition

Addressing Failures in Lead Candidate Criteria Prior to IND-Enabling Studies In the drug development landscape, the failure of a lead candidate during downstream criteria assessment can be a significant setback,…

Reproducibility issues in screening data during translational assessment – decision framework regulators expect

Addressing Reproducibility Issues in Screening Data During Translational Assessment Reproducibility issues in screening data can significantly impact the trajectory of drug development, particularly during the critical phase of translational assessment…

Target validation uncertainty before IND-enabling studies – how to avoid late-stage attrition

Addressing Target Validation Uncertainty Ahead of IND-Enabling Studies Target validation is a crucial phase in drug discovery, yet uncertainty at this stage can lead to significant challenges, especially when transitioning…

Off-target toxicity signals during early discovery – impact on IND success probability

Understanding Off-target Toxicity Signals and Their Impact on IND Success Probability In recent years, an increasing number of pharmaceutical companies have reported challenges related to off-target toxicity signals during early…

Reproducibility issues in screening data during portfolio review – decision framework regulators expect

Addressing Reproducibility Issues in Screening Data During Portfolio Evaluations In the pharmaceutical sector, inconsistent screening data can hinder the transition of promising compounds through the drug development pipeline, impacting decision-making…

Off-target toxicity signals during early discovery – risk mitigation strategy

Identifying and Mitigating Off-Target Toxicity Signals in Early Drug Discovery In the realm of pharmaceutical research, the early stages of drug discovery play a pivotal role in assessing the potential…

Poor hit-to-lead progression before IND-enabling studies – how to avoid late-stage attrition

“`html Understanding and Addressing Poor Hit-to-Lead Progression Before IND-Enabling Studies Poor hit-to-lead progression can derail drug discovery efforts and significantly delay the initiation of Investigational New Drug (IND)-enabling studies. In…

Off-target toxicity signals during translational assessment – risk mitigation strategy

Mitigating Risks of Off-Target Toxicity Signals During Translational Assessment In the complex landscape of pharmaceutical development, detecting off-target toxicity signals during translational assessment poses a significant risk to the success…

Lead candidate fails downstream criteria before IND-enabling studies – decision framework regulators expect

“`html Evaluating the Failure of a Lead Candidate in Downstream Criteria Prior to IND-Enabling Studies In the complex world of drug discovery, the progression of a lead candidate through various…

ADME liabilities identified late during portfolio review – impact on IND success probability

“`html Understanding Late-Identified ADME Liabilities and Their Impact on IND Success In the complex landscape of drug development, late identification of Absorption, Distribution, Metabolism, and Excretion (ADME) liabilities can prove…

Poor hit-to-lead progression before IND-enabling studies – impact on IND success probability

Analyzing Poor Hit-to-Lead Progression Before IND-Enabling Studies and Its Impact on IND Success In the pharmaceutical industry, the successful transition from hit-to-lead compounds to IND-enabling studies is critical for ensuring…

Lead candidate fails downstream criteria before IND-enabling studies – impact on IND success probability

Investigation of Lead Candidate Failure in Downstream Criteria Prior to IND-Enabling Studies In the intricate world of drug discovery, a lead candidate that fails to meet downstream criteria before Investigational…